# US 11,896,043 B2 · Intestinal immune-enhancing agent, food product, and medicament

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,043 B2
- Document ID: US11896043B2
- Status: Granted
- Kind: B2
- Application number: 17/476,131
- Filed: 2021-09-15
- Published: 2022-03-03
- Granted: 2024-02-13
- Earliest claimed: 2017-10-26
- Assignees: Daicel Corporation
- Applicants: Daicel Corporation
- Inventors: Tadashi Takeuchi; Eiji Miyauchi; Shu Shimamoto; Akinobu Matsuyama; Hiroshi Ohno
- Web page: https://patentgrep.com/patent/US11896043B2

## CPC

- A23L 33/24: Cellulose or derivatives thereof
- A23L 33/125: containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates (indigestible substances A23L33/21)
- A61K 31/717: Celluloses
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G06F 17/18: for evaluating statistical data {, e.g. average values, frequency distributions, probability functions, regression analysis (forecasting specially adapted for a specific administrative, business or logistic context G06Q10/04)}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G06F: ELECTRIC DIGITAL DATA PROCESSING (computer systems based on specific computational models G06N)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Object of the present invention is to provide an intestinal immune-enhancing agent that can sufficiently increase IgA in the intestinal tract with a low dose while maintaining an increased amount of IgA for an extended period of time. Provided is an intestinal immune-enhancing agent containing a cellulose acetate that has a total degree of acetyl substitution from 0.4 to 1.1.

## Claims

### Claim 1

A method for increasing and maintaining of IgA in the intestinal tract of a subject in need thereof, comprising
intaking by the subject or administering to the subject a cellulose acetate having a total degree of acetyl substitution from 0.4 to 1.1;
wherein an intake or administration dose per serving is from 5 mg/kg body weight to 60 mg/kg body weight.

### Claim 2 (depends on 1)

The method for increasing and maintaining of IgA in the intestinal tract according to claim 1, wherein the cellulose acetate has a compositional distribution index (CDI) of 2.0 or less, the compositional distribution index (CDI) being defined by the equation below:
CDI=(Measured value of half width of compositional distribution/(Theoretical value of half width of compositional distribution)
wherein the measured value of half width of compositional distribution is a half width of compositional distribution determined by high-performance liquid chromatographic analysis of a cellulose acetate propionate obtained by propionylation of all residual hydroxyl groups of a cellulose acetate,
where DS is the total degree of acetyl substitution; and
the theoretical value of half width of compositional distribution=2.35482√{square root over (3*DPw*(DS/3)*(1−DS/3))}/DPw
Dpw is a weight average degree of polymerization determined by gel permeation chromatography-light scattering method using a cellulose acetate propionate obtained by propionylation of all residual hydroxyl groups of the cellulose acetate.

### Claim 3

A method for treating infections caused by pathogenic bacteria belonging to the phylum Proteobacteria in a subject, where the pathogenic bacteria are Salmonella, cholera, or Vibrio parahaemolyticus,
the method comprising
intaking by the subject or administering to the subject a cellulose acetate having a total degree of acetyl substitution from 0.4 to 1.1;
wherein an intake or administration dose per serving is from 5 mg/kg body weight to 60 mg/kg body weight.

### Claim 4 (depends on 3)

The method for treating infections caused by pathogenic bacteria, belonging to the phylum Proteobacteria according to claim 3, wherein the cellulose acetate has a compositional distribution index (CDI) of 2.0 or less, the compositional distribution index (CDI) being defined by the equation below:
CDI=(Measured value of half width of compositional distribution)/(Theoretical value of half width of compositional distribution)
wherein the measured value of half width of compositional distribution is a half width of compositional distribution determined by high-performance liquid chromatographic analysis of a cellulose acetate propionate obtained by propionylation of all residual hydroxyl groups of a cellulose acetate,
where DS is the total degree of acetyl substitution; and
the theoretical value of half width of compositional distribution=2.35482√{square root over (3*DPw*(DS/3)*(1−DS/3))}/DPw
Dpw is a weight average degree of polymerization determined by gel permeation chromatography-light scattering method using a cellulose acetate propionate obtained by propionylation of all residual hydroxyl groups of the cellulose acetate.

### Claim 5

A method for increasing and maintaining of IgA in the intestinal tract of a subject infected with pathogenic bacteria belonging to the phylum Proteobacteria, comprising
intaking by the subject or administering to the subject a water-soluble dietary fiber selected from a cellulose acetate having a total degree of acetyl substitution from 0.4 to 1.1;
wherein an intake or administration dose per serving is from 5 mg/kg body weight to 60 mg/kg body weight.